



PTO/SB/08A (07-06)

Approved for use through 09/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/668,045
Filing Date	September 22, 2003
First Named Inventor	Chau et al.
Art Unit	1618
Examiner Name	Rogers, J.W.

Sheet 1 Of 1 Attorney Docket Number 0492611-0505 (MIT 9991)

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
GJ		US-6,372,205	April 16, 2002	Duncan et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶

Examiner Signature	<i>O. May</i>	Date Considered	5/5/07
--------------------	---------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

4137381v1

BEST AVAILABLE COPY

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/668,045
				Filing Date	September 22, 2003
				First Named Inventor	Chau et al.
				Art Unit	1618
				Examiner Name	Rogers, J.W.
Sheet	1	Of	2	Attorney Docket Number	0492611-0505 (MIT 9991)

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>JN</i>		Chau et al., "Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models", <i>Int. J. Cancer</i> , 118:1519-1526, , 2006.	
		Chau et al., "Synthesis and characterization of dextran-peptide-methotrexate conjugates for tumor targeting via mediation by matrix metalloproteinase II and matrix metalloproteinase IX", <i>Bioconjugate Chem.</i> , 15: 931-941, 2004.	
		Corticchiato et al., "Cystatin-C and cathepsin-B in human colon-carcinoma-expression by cell-lines and matrix degradation", <i>Int. J. Cancer</i> , 52: 645-652, 1992.	
		Duncan et al., "Preclinical evaluation of polymer-bound doxorubicin", <i>J. Controlled Release</i> , 19: 331-346, 1992.	
		Duncan et al., "Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to the clinic", <i>J. Controlled Release</i> , 74:135-146, 2001.	
		Duncan et al., "Polymer-drug conjugates: towards a novel approach for the treatment of endocrine-related cancer", <i>Endocrine-Related Cancer</i> , 12:S189-S199, 2005.	
		Hopewell et al., "Preclinical evaluation of the cardiotoxicity of PK2: a novel HPMA copolymer-doxorubicin-galactosamine conjugate antitumour agent", <i>Hum. Exp. Toxicol.</i> , 20: 461-470, 2001.	
		Jane et al., "Cathepsin B localizes to plasma membrane caveolae of differentiating myoblasts and is secreted in an active form at physiological pH", <i>Biol. Chem.</i> , 387: 223-234, 2006.	
		Khalfan, "Study of thiol proteases of normal human skin fibroblasts", <i>Cell Biochemistry and Function</i> , 9:55-62, 1991.	
<i>JN</i>		Linebaugh et al., "Exocytosis of active cathepsin B enzyme activity at pH 7.0, inhibition and molecular mass" <i>Eur. J. Biochem.</i> , 264:100-109, 1999.	
<i>JN</i>		Loadman et al., "Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1", <i>Clin. Cancer Res.</i> , 5:3682-3688, 1999.	

<i>JN</i>	Moin <i>et al.</i> , "Tumor cell membrane cathepsin B", <i>Biol. Chem.</i> , 379:1093-1099, 1998.	
	Noguchi <i>et al.</i> , "Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues", <i>Jpn. J. Cancer Res.</i> , 89:307-314, 1998.	
	Ruzza <i>et al.</i> , "Fluorescent, internally quenched, peptides for exploring the pH-dependent substrate specificity of cathepsin B" <i>J. Pept. Sci.</i> , 12:455-461, 2006.	
	Seymour <i>et al.</i> , "The pharmacokinetics of polymer-bound adriamycin", <i>Biochem. Pharmacol.</i> , 39:1125-1131, 1990.	
	Seymour <i>et al.</i> , "Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma", <i>British J. Cancer</i> , 70:636-641, 1994.	
<i>U</i>	Song <i>et al.</i> , "The active-site residue Cys-29 is responsible for the neutral-pH inactivation and the refolding barrier of human cathepsin B", <i>FEBS Lett.</i> , 475:157-162, 2000.	
<i>JN</i>	Vasey <i>et al.</i> , "Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates", <i>Clin. Cancer Res.</i> , 5: 83-94, 1999.	

Examiner Signature	<i>Olney</i>	Date Considered	<i>3/5/07</i>
-----------------------	--------------	--------------------	---------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 2313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.